ID   UKF-NB-6rNutlin10muM
AC   CVCL_RS15
DR   cancercelllines; CVCL_RS15
DR   Wikidata; Q54990396
RX   PubMed=22170099;
RX   PubMed=24466371;
WW   https://www.wass-michaelislab.org/rccl.php
CC   Part of: Resistant Cancer Cell Line (RCCL) collection.
CC   Selected for resistance to: ChEBI; CHEBI:46742; Nutlin-3.
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Asn (c.396G>T); ClinVar=VCV000634773; Zygosity=Unspecified (PubMed=22170099).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223Leu (c.668C>T); ClinVar=VCV000234214; Zygosity=Unspecified (PubMed=22170099).
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_M474 ! UKF-NB-6
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 05-10-23; Version: 10
//
RX   PubMed=22170099; DOI=10.1038/cddis.2011.129;
RA   Michaelis M., Rothweiler F., Barth S., Cinatl J., van Rikxoort M.,
RA   Loschmann N., Voges Y., Breitling R., von Deimling A., Rodel F.,
RA   Weber K., Fehse B., Mack E., Stiewe T., Doerr H.-W., Speidel D.,
RA   Cinatl J. Jr.;
RT   "Adaptation of cancer cells from different entities to the MDM2
RT   inhibitor nutlin-3 results in the emergence of p53-mutated
RT   multi-drug-resistant cancer cells.";
RL   Cell Death Dis. 2:e243.1-e243.8(2011).
//
RX   PubMed=24466371; DOI=10.1593/tlo.13544;
RA   Loschmann N., Michaelis M., Rothweiler F., Zehner R., Cinatl J.,
RA   Voges Y., Sharifi M., Riecken K., Meyer J., von Deimling A.,
RA   Fichtner I., Ghafourian T., Westermann F., Cinatl J. Jr.;
RT   "Testing of SNS-032 in a panel of human neuroblastoma cell lines with
RT   acquired resistance to a broad range of drugs.";
RL   Transl. Oncol. 6:685-696(2013).
//